SCHEMBL18769986

SCHEMBL18769986

COC(OC)C(=O)NCc1ccc(Cl)c(Cl)c1

nearest known ligand 0.69

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.69
SMN1; SMN2 Q16637 1/20 0.58
LMNA P02545 2/20 0.54
HRH3 Q9Y5N1 1/20 0.53
HPGD P15428 1/20 0.52
APEX1 P27695 1/20 0.51
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
ALDH1A1 P00352 1/20 0.49
F7 P08709 1/20 0.47
TRPV1 Q8NER1 1/20 0.47
CTSD P07339 1/20 0.45
P2RX7 Q99572 2/20 0.45
MAPT P10636 1/20 0.45
MAPK1 P28482 1/20 0.45
EPHX2 P34913 1/20 0.44
TAOK1 Q7L7X3 1/20 0.44
TAOK3 Q9H2K8 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18769917 0.88 TSHR (0.54) TSHRSMN1; SMN2LMNAHRH3MAPT
SCHEMBL18769973 0.87 TSHR (0.52) TSHRSMN1; SMN2MEN1KMT2AALDH1A1
SCHEMBL29567928 0.87 TSHR (0.52) TSHRSMN1; SMN2MEN1KMT2AALDH1A1
SCHEMBL18791419 0.87 TSHR (0.68) TSHRSMN1; SMN2LMNAHRH3HPGD
SCHEMBL2750084 0.83 MEN1 (0.58) TSHRSMN1; SMN2HPGDMEN1KMT2A
SCHEMBL8310378 0.83 TSHR (0.66) TSHRSMN1; SMN2LMNAHRH3HPGD
SCHEMBL2750482 0.81 APEX1 (0.54) LMNAAPEX1KMT2AALDH1A1CTSD
SCHEMBL18133710 0.80 TSHR (0.62) TSHRSMN1; SMN2LMNAHRH3HPGD
SCHEMBL18791331 0.80 CARM1 (0.49) TSHRALDH1A1TRPV1CTSD
Hydrochloric Acid SCHEMBL18130580 0.79 TSHR (0.60) TSHRSMN1; SMN2LMNAHRH3HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3365061-A1 AMINOISOXAZOLINE COMPOUNDS AS AGONISTS OF ALPHA7-NICOTINIC ACETYLCHOLINE RECEPTORS Axovant Sciences GmbH (DE) 2018-08-29 EP disclosed
US-20170247393-A1 Aminoisoxazoline Compounds as Agonists of Alpha7-Nicotinic Acetylcholine Receptors FORUM PHARMACEUTICALS, INC. 2017-08-31 US disclosed
US-20170247393-A1 Aminoisoxazoline Compounds as Agonists of Alpha7-Nicotinic Acetylcholine Receptors FORUM PHARMACEUTICALS, INC. 2017-08-31 US disclosed
US-20170247393-A1 Aminoisoxazoline Compounds as Agonists of Alpha7-Nicotinic Acetylcholine Receptors FORUM PHARMACEUTICALS, INC. 2017-08-31 US disclosed
WO-2017069980-A1 AMINOISOXAZOLINE COMPOUNDS AS AGONISTS OF ALPHA7-NICOTINIC ACETYLCHOLINE RECEPTORS FORUM PHARMACEUTICALS, INC. (US) 2017-04-27 WO disclosed
WO-2017069980-A1 AMINOISOXAZOLINE COMPOUNDS AS AGONISTS OF ALPHA7-NICOTINIC ACETYLCHOLINE RECEPTORS FORUM PHARMACEUTICALS, INC. (US) 2017-04-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170247393-A1 Aminoisoxazoline Compounds as Agonists of Alpha7-Nicotinic Acetylcholine Receptors CHRNA7, CHRNA5, CHRNA2 TSHR 583/4885SMN1; SMN2 696/4885LMNA 1872/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.